The Italian Drug Agency (AIFA) approved today the injection of the vaccine “Comirnaty” (Pfizer) against COVID-19 in children between 5 and 11 years of age, following the authorization of the European Medicines Agency (EMA) of the last october.
The drug will be injected with a dose of a third of that applied in adults and adolescents and with a specific formula, according to a statement published after the meeting held by the AIFA scientific technical commission.
The vaccination will be carried out with two doses with an interval of three weeks between the first and the second.
The AIFA ensures that the available data “demonstrate a high level of efficacy and there are no warning signs in terms of safety at the moment.”
In this sense, it is recalled that although infections by the Sars-CoV-2 virus are “more benign in children, in some cases they can be associated with serious consequences” such as the development of multisystemic inflammatory syndrome that can lead to intensive care.
The entity recalls that one of the benefits of vaccination is the possibility that children can go to school and have a social life, aspects “particularly important for psychic and personality development in this age group.”
The EMA already supported on November 25 the extension of the current European license of the pharmaceutical companies Pfizer and BioNTech for the use of their vaccine against covid-19 in children between 5 and 11 years old, Comirnaty, its commercial name.